^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Follicular Lymphoma
    Regimen:G-CHOP (cyclophosphamide + doxorubicin hydrochloride + Gazyva (obinutuzumab) + + vincristine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    01/20/2021
    Excerpt:
    Follicular Lymphoma: FIRST-LINE THERAPY…Preferred Regimens…CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) + Obinutuzumab or rituximab